Albert Paszek

Dr. Albert Paszek joined Mustang in October 2019 as the Head of Manufacturing Science and Technology, where he is responsible for development and operations needed for execution of GMP Manufacturing of CAR-T and X-SCID therapies. Dr. Paszek was previously a Senior Director of Manufacturing and Operations at Abeona Therapeutics and led development of manufacturing processes for cell and gene therapies for rare genetic diseases with focus on the Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Sanfilippo Syndrome Types A and B. Earlier in his career, Dr. Paszek was a Senior Director of Technical Services at Alexion Pharmaceuticals with responsibility for multiple bioreactor platforms, and a Senior Director and Site Head for the Synageva Biopharma Corporation where he led CMC development actions and preparation of successful FDA, EMA and Japanese applications for approval of the Kanuma® enzyme replacement therapeutic for treatment of the Lysosomal Acid Lipase Deficiency (LAL-D). His leadership included the design, construction, startup and operation of two GMP manufacturing facilities and one development site. Dr. Paszek has also led development of genomic diagnostic technologies for improvement and management of genetic resources used by biotech and food manufacturing industries. He has held faculty and academic appointments at the University of Minnesota, executing projects based on industry collaborations and aimed at the development of biotech technologies involving genomics. Dr. Paszek holds his Ph.D. and Post-Doctoral experience in Genetics and Genomics from the University of Minnesota.